• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

Recent Advances in the Study of 3-Formylbenzene-1-carboximidamide (CAS: 73358-99-3) in Chemical Biology and Pharmaceutical Research

3-Formylbenzene-1-carboximidamide (CAS: 73358-99-3) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its formyl and carboximidamide functional groups, has been the subject of recent studies due to its potential applications in drug discovery and development. The unique structural features of 3-formylbenzene-1-carboximidamide make it a promising candidate for the synthesis of novel bioactive molecules, particularly in the areas of antimicrobial and anticancer agents.

Recent research has focused on the synthesis and characterization of 3-formylbenzene-1-carboximidamide derivatives to explore their biological activities. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that certain derivatives of this compound exhibit potent inhibitory effects against bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The study utilized a combination of computational modeling and in vitro assays to identify key structural modifications that enhance antimicrobial activity while minimizing cytotoxicity.

In addition to its antimicrobial potential, 3-formylbenzene-1-carboximidamide has also been investigated for its role in cancer therapy. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that this compound can act as a precursor for the synthesis of small-molecule inhibitors targeting specific oncogenic pathways. The researchers highlighted its ability to modulate the activity of kinases involved in tumor proliferation, suggesting its utility in the development of targeted cancer therapies.

The pharmacokinetic properties of 3-formylbenzene-1-carboximidamide and its derivatives have also been a focus of recent investigations. A preclinical study conducted by a team at the University of Cambridge (2024) evaluated the absorption, distribution, metabolism, and excretion (ADME) profiles of several derivatives. The findings indicated that these compounds exhibit favorable bioavailability and metabolic stability, making them suitable candidates for further drug development.

Despite these promising findings, challenges remain in the optimization of 3-formylbenzene-1-carboximidamide-based therapeutics. Issues such as selectivity, off-target effects, and potential toxicity need to be addressed through rigorous structure-activity relationship (SAR) studies. Future research directions may include the exploration of novel delivery systems, such as nanoparticle-based formulations, to enhance the efficacy and safety of these compounds.

In conclusion, 3-formylbenzene-1-carboximidamide (CAS: 73358-99-3) represents a versatile scaffold in chemical biology and pharmaceutical research. Its potential applications in antimicrobial and anticancer therapy, coupled with its favorable pharmacokinetic properties, underscore its importance as a subject of ongoing investigation. Continued research efforts are expected to yield innovative therapeutic agents derived from this compound, addressing unmet medical needs in various disease areas.

• 55514-20-0(4-Formyl-benzamidine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)